share_log

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Mahatme Sandesh

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Mahatme Sandesh

CRISPR Therapeutics | 3:首次持股聲明-董事 Mahatme Sandesh
美股SEC公告 ·  05/30 16:34
Moomoo AI 已提取核心訊息
Sandesh Mahatme, a director and 10% owner of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 30, 2024. The filing, submitted on Form 3, indicates Mahatme's beneficial ownership of non-derivative securities, specifically 26,000 common shares of CRISPR Therapeutics, which are subject to a stock option right to buy at a price of $44.81 per share. The option was granted on October 16, 2023, and is set to vest over 36 months, with the first installment vesting on November 16, 2023. The form was filed as a single reporting person and included a Power of Attorney signed by Sandesh Mahatme.
Sandesh Mahatme, a director and 10% owner of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 30, 2024. The filing, submitted on Form 3, indicates Mahatme's beneficial ownership of non-derivative securities, specifically 26,000 common shares of CRISPR Therapeutics, which are subject to a stock option right to buy at a price of $44.81 per share. The option was granted on October 16, 2023, and is set to vest over 36 months, with the first installment vesting on November 16, 2023. The form was filed as a single reporting person and included a Power of Attorney signed by Sandesh Mahatme.
CRISPR Therapeutics的董事兼10%所有者桑德什·馬哈特梅於2024年5月30日向美國證券交易委員會提交了初步的證券實益擁有權聲明。該文件以表格3提交,顯示了聖雄對非衍生證券的受益所有權,特別是CRISPR Therapeutics的26,000股普通股,這些股票受股票期權的約束,可以以每股44.81美元的價格購買。該期權於2023年10月16日授予,定於36個月內歸屬,第一期將於2023年11月16日解鎖。該表格是作爲單一舉報人提交的,其中包括一份由桑德什·馬哈特姆簽署的委託書。
CRISPR Therapeutics的董事兼10%所有者桑德什·馬哈特梅於2024年5月30日向美國證券交易委員會提交了初步的證券實益擁有權聲明。該文件以表格3提交,顯示了聖雄對非衍生證券的受益所有權,特別是CRISPR Therapeutics的26,000股普通股,這些股票受股票期權的約束,可以以每股44.81美元的價格購買。該期權於2023年10月16日授予,定於36個月內歸屬,第一期將於2023年11月16日解鎖。該表格是作爲單一舉報人提交的,其中包括一份由桑德什·馬哈特姆簽署的委託書。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息